Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters

WSW, NY, June 17th, 2026, FinanceWire

Rhythm’s latest rare-obesity win strengthens the MC4R thesis - making Palatin’s more selective, next-generation approach one of the small-cap biotech stories to watch

Positive six-month data that Rhythm Pharmaceuticals (Nasdaq: RYTM) presented at the ENDO 2026 medical meeting on June 13 added fresh clinical evidence for a drug target that a much smaller competitor, Palatin Technologies (Nasdaq: PTN), is building its future around. Rhythm’s market capitalization is hovering around $6.5 billion, while Palatin’s is hovering around $21 million. The results, from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), point to the continued therapeutic promise of activating the melanocortin-4 receptor (MC4R), a brain pathway that helps control appetite and body weight.

PWS is a rare genetic disorder marked by relentless hunger, or hyperphagia, that drives severe obesity and has limited treatment options. In the interim analysis, setmelanotide was associated with mean body mass index reductions of 3.11% in adults (n=10) and 3.00% in pediatric patients (n=7), alongside improvements in hyperphagia, body composition, and anxiety measures. Seventeen of the 18 enrolled patients remained on therapy as of mid-June, and Rhythm said the findings support advancing MC4R agonism toward a Phase 3 trial in PWS.

Read narrowly, that is a win for Rhythm as the commercial leader in this space. But the data may carry broader meaning. Each positive MC4R study reinforces the underlying biology, even if it does not remove the molecule-specific safety, efficacy, and regulatory risk that any individual program still has to clear.

Rhythm has spent years establishing that case, with its approved MC4R therapy now spanning several rare obesity indications, including hypothalamic obesity. Palatin has been working in melanocortin receptor science for decades. The company says it has assembled a data-driven platform refined over decades of melanocortin research, with peptide and small-molecule candidates tested for activity at MC4R and MC1R and spanning potency and efficacy, receptor signaling, structure-activity relationships, selectivity, and animal results.

Where first-generation MC4R drugs activate the target broadly, Palatin’s strategy centers on selectivity and long-term tolerability. The company is designing candidates that hit MC4R while minimizing activity at MC1R, a neighboring receptor that controls skin pigmentation. MC1R activity is a known contributor to hyperpigmentation, or skin darkening, one of the most recognizable side effects of currently available MC4R therapy. Palatin reports that its next-generation peptide and oral candidates show substantially improved MC4R selectivity over earlier compounds. The company believes that improved selectivity could meaningfully reduce, and potentially eliminate, hyperpigmentation, and that these attributes could translate into improved long-term tolerability, usability, and patient adherence. Whether those preclinical advantages hold up in people will be determined in clinical trials.

Palatin is advancing two programs built on that approach, informed by insights from its decades of MC4R research and development. A once-weekly injectable MC4R peptide is on track for an investigational new drug (IND) submission, the regulatory step required to begin human testing, in the fourth quarter of calendar 2026. A next-generation oral MC4R candidate is targeted for an IND in the first half of 2027. The company’s planned clinical focus spans hypothalamic obesity, PWS, and Bardet-Biedl syndrome, the same rare obesity populations in which Rhythm has helped establish the clinical relevance of MC4R agonism.

That overlap is significant. Validating a pathway is often only the first chapter of a therapeutic category. First-generation therapies are frequently followed by products designed to improve convenience, tolerability, and the overall patient experience, particularly in chronic diseases where adherence is critical. Palatin is positioning its candidates for exactly that setting. If its enhanced selectivity profile translates clinically, the company may have an opportunity to offer differentiated options for patients with rare obesity disorders while building on the foundation established by the first generation.

Viewed through that lens, Rhythm’s recent PWS results may represent more than a single company’s clinical study readout. They serve as another validation point for the broader MC4R category, and for the companies, Palatin among them, working to develop the next generation of therapies targeting this pathway.

Read this Next >>

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know (NYSE: NVO) (NYSE: LLY)

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer (Nasdaq: ELTX)

Recent News Highlights From Palatin (NASDAQ: PTN)

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Palatin Technologies, Inc. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact